Yohei Arihara

Yohei Arihara

Auto-generated profile, based on publicly available information

Yohei Arihara

Dana-Farber Cancer Institute, Boston, Massachusetts

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 October 2023 in Japanese Journal of Clinical Oncology
Verified
Journal Article
Open access
PDF file
TKTomohiro Kubo
Tomohiro Kubo
JMJoji Muramatsu
Joji Muramatsu
YAYohei Arihara
Yohei Arihara
AMAyako Murota
Ayako Murota
KIKazuma Ishikawa
Kazuma Ishikawa
KTKohichi Takada
Kohichi Takada
Accumulating evidence has demonstrated platinum-based chemotherapy followed by maintenance therapy with a poly Adenosine diphosphate (ADP)-ribose polymerase inhibitor (olaparib) show benefits in unresectable pancreatic cancer with a germline (g)BRCA1/2 mutation. Evaluation of the germline BRCA1 and BRCA2 mutation is essential for making decisions on a treatment strategy for patients with unresectable pancreatic cancer. However, the detection rates of germline BRCA1 and BRCA2 mutations and efficacy of maintenance with olaparib remain undetermined, prospectively, in Japan. In this prospective analysis, the rate of germline BRCA1 and BRCA2 mutations and efficacy of chemotherapy were analyzed in 136 patients with pancreatic cancer who underwent BRACAnalysis® (85 patients) or FoundationOne® CDx (51 patients) between January 2020 and July 2022. A total of six patients (4.4%) had a germline BRCA1 and BRCA2 mutation. Five patients were treated with modified FOLFIRINOX and one with fluorouracil and oxaliplatin. All patients continued platinum-based chemotherapy for ˃4 months and were subsequently treated with olaparib as a maintenance therapy. The response rate to platinum-based chemotherapy in the germline BRCA1 and BRCA2 mutation-positive group was significantly better than that of the germline BRCA1 and BRCA2 mutation-negative group (66% vs 23%, P = 0.04). All patients harbouring a germline BRCA1 and BRCA2 mutation were able to switch to olaparib. The median progression-free survival using olaparib was 5.7 months (range 3.0–9.2). The rate of germline BRCA1 and BRCA2 mutations found in patients with unresectable pancreatic cancer was comparable to those of previous studies. An analysis of germline BRCA1 and BRCA2 mutations has benefits for all patients with unresectable pancreatic cancer with regard to decisions on therapeutic strategies in a clinical practice setting.

13 November 2025 in Clinical Cancer Research
Verified
Journal Article
Open access
CJCaron A. Jacobson
Caron A. Jacobson
JWJason R. Westin
Jason R. Westin
DMDavid B. Miklos
David B. Miklos
AHAlex F. Herrera
Alex F. Herrera
JRJerome Ritz
Jerome Ritz
FLFrederick L Locke
Frederick L Locke
Purpose: Chimeric antigen receptor (CAR) T-cell therapies have improved outcomes in patients with relapsed/refractory large B-cell lymphoma (LBCL). However, up to two thirds of these patients do not maintain long-term responses. The phase 1/2 ZUMA-6 study investigated the feasibility of combining the CD19-directed CAR T-cell therapy axicabtagene ciloleucel (axi-cel) with the PD-L1 inhibitor atezolizumab as a potential approach to increase treatment efficacy while maintaining acceptable safety. Patients and Methods: Patients with refractory diffuse LBCL received a single axi-cel infusion (2 × 106 cells/kg), followed by atezolizumab 1,200 mg i.v. every 21 days for four cycles. Primary endpoints were dose-limiting toxicities (phase 1) and complete response rate (phase 2). Other efficacy and safety outcomes and pharmacokinetics/pharmacodynamics were assessed. Results: Overall, 34 patients received axi-cel plus atezolizumab in ZUMA-6. The median follow-up for the final analysis was 56.9 months. In phase 1, one patient experienced dose-limiting toxicities (grade 4 neutropenia and thrombocytopenia). Thirty patients (88%) experienced grade ≥3 treatment-emergent adverse events. Three (9%) and 11 (32%) patients experienced grade ≥3 cytokine release syndrome and neurologic events, respectively. In the final analysis, 15 patients (54%) had a complete response. The median progression-free survival and overall survival were 9 and 32.2 months, respectively. Peak CAR T-cell and cytokine profiles were comparable with those previously reported for axi-cel monotherapy (ZUMA-1). Conclusions: Axi-cel plus atezolizumab had a manageable safety profile, with no new safety signals. Safety and efficacy of this combination were consistent with axi-cel monotherapy. Correlative analyses could inform with regard to which patients with LBCL may benefit from axi-cel and immune checkpoint inhibitor combinations.

24 June 2024 in Cancer Reports
Verified
Journal Article
Open access
YAYohei Arihara
Yohei Arihara
GOGinji Omori
Ginji Omori
KKKo Kobayashi
Ko Kobayashi
SSShintaro Sugita
Shintaro Sugita
KMKazuyuki Murase
Kazuyuki Murase
KTKohichi Takada
Kohichi Takada
Background: SMARCA4 is a component gene of the SWI/SNF (SWItch/Sucrose NonFermentable) chromatin remodeling complex; undifferentiated tumors associated with its functional deletion have been described in several organs. However, no established treatment for these tumors currently exists.Case: In this study, we report a case of a SMARCA4‐deficient undifferentiated urothelial carcinoma with high PD‐L1 expression that was effectively treated with nivolumab after early relapse following treatment for non‐invasive bladder cancer. The histological morphology of the rhabdoid‐like undifferentiated tumor of unknown primary led us to suspect a SWI/SNF‐deficient tumor, and subsequent immunostaining led to the diagnosis of a SMARCA4‐deficient undifferentiated tumor. This effort also led to the identification of the developmental origin of this SMARCA4‐deficient undifferentiated tumor as a non‐invasive bladder cancer. We also carried out a detailed immune phenotypic assay on peripheral T cells. In brief, a phenotypic change of CD8+T cells from naive to terminally differentiated effector memory cells was observed.Conclusion: Regardless of the organ of cancer origin or cancer type, SWI/SNF‐deficient tumors should be suspected in undifferentiated and dedifferentiated tumors, and immune checkpoint inhibitors may be considered as a promising treatment option for this type of tumor. The pathogenesis of SMARCA4‐deficient anaplastic tumors awaits further elucidation for therapeutic development.

7 December 2023 in Palliative Medicine Reports
Verified
Journal Article
Open access
YAYohei Arihara
Yohei Arihara
RSRyo Shibuya
Ryo Shibuya
MOMichihiro Ono
Michihiro Ono
NSNorito Suzuki
Norito Suzuki
GOGinji Omori
Ginji Omori
MMMasahiro Maeda
Masahiro Maeda
Background: Due to the lack of studies, the long-term prognoses of unfit patients with gastric cancer (GC) who did not receive any aggressive cancer treatment (best supportive care [BSC] cases) remain unclear, especially for those with potentially curable GC. We conducted this observational study to capture the real-world data of characteristics and outcomes for BSC cases. Method: Consecutive clinical records of patients with GC diagnosed at Steel Memorial Muroran Hospital from January 2017 to December 2021 were analyzed. Result: Of 481 patients diagnosed with GC, 91 (18.9%) were BSC cases. The median overall survival (OS) was 12.4, 8.3, and 2.5 months for clinical stage (cStage) I, II–III, and IV, respectively. Patients with potentially curable GC (cStage I–III) had significantly longer OS than those with incurable disease (cStage IV), with a hazard ratio for death of 0.29 (95% confidence interval: 0.18–0.47). Conclusion: Our report provides useful information for decision-making for unfit patients with GC in daily clinical practice.


2 March 2026
Verified
Other
Open access
PDF file
CJCaron A. Jacobson
Caron A. Jacobson
JWJason R. Westin
Jason R. Westin
DMDavid B. Miklos
David B. Miklos
AHAlex F. Herrera
Alex F. Herrera
JRJerome Ritz
Jerome Ritz
FLFrederick L Locke
Frederick L Locke
Associations of PD-L1 and CD19 biomarkers and baseline tumor burden with objective response